| Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis AM Petrich, M Gandhi, B Jovanovic, JJ Castillo, S Rajguru, DT Yang, ... Blood, The Journal of the American Society of Hematology 124 (15), 2354-2361, 2014 | 519 | 2014 |
| Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment Y Liu, SK Barta American journal of hematology 94 (5), 604-616, 2019 | 449 | 2019 |
| Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology PL Greenberg, RM Stone, A Al-Kali, SK Barta, R Bejar, JM Bennett, ... Journal of the National Comprehensive Cancer Network 15 (1), 60-87, 2017 | 325 | 2017 |
| Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients SK Barta, X Xue, D Wang, R Tamari, JY Lee, N Mounier, LD Kaplan, ... Blood, The Journal of the American Society of Hematology 122 (19), 3251-3262, 2013 | 215 | 2013 |
| 2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management S Susanibar‐Adaniya, SK Barta American journal of hematology 96 (5), 617-629, 2021 | 195 | 2021 |
| Outcomes of patients with double-hit lymphoma who achieve first complete remission DJ Landsburg, MK Falkiewicz, J Maly, KA Blum, C Howlett, T Feldman, ... Journal of Clinical Oncology 35 (20), 2260, 2017 | 164 | 2017 |
| Acute lymphoblastic leukemia, version 2.2015 JC Alvarnas, PA Brown, P Aoun, KK Ballen, SK Barta, U Borate, ... Journal of The national comprehensive cancer network 13 (10), 1240-1279, 2015 | 136 | 2015 |
| Clinical pharmacokinetics and pharmacodynamics of bortezomib CRC Tan, S Abdul-Majeed, B Cael, SK Barta Clinical pharmacokinetics 58, 157-168, 2019 | 115 | 2019 |
| A phase I study of a combination of anti‐CD19 and anti‐CD22 immunotoxins (Combotox) in adult patients with refractory B‐lineage acute lymphoblastic leukaemia J Schindler, S Gajavelli, F Ravandi, YM Shen, S Parekh, I Braunchweig, ... British journal of haematology 154 (4), 471-476, 2011 | 113 | 2011 |
| Changes in the influence of lymphoma-and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma SK Barta, MS Samuel, X Xue, D Wang, JY Lee, N Mounier, JM Ribera, ... Annals of Oncology 26 (5), 958-966, 2015 | 109 | 2015 |
| Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma SK Barta, J Zain, AW MacFarlane IV, SM Smith, J Ruan, HC Fung, CR Tan, ... Clinical Lymphoma Myeloma and Leukemia 19 (6), 356-364. e3, 2019 | 106 | 2019 |
| Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV‐associated non‐Hodgkin lymphoma SK Barta, JY Lee, LD Kaplan, A Noy, JA Sparano Cancer 118 (16), 3977-3983, 2012 | 105 | 2012 |
| Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre … CS Diefenbach, F Hong, RF Ambinder, JB Cohen, MJ Robertson, ... The Lancet Haematology 7 (9), e660-e670, 2020 | 94 | 2020 |
| Intensity dependence of auditory evoked potentials (AEPs) as biological marker for cerebral serotonin levels: effects of tryptophan depletion in healthy subjects T Dierks, S Barta, L Demisch, K Schmeck, E Englert, A Kewitz, K Maurer, ... Psychopharmacology 146, 101-107, 1999 | 90 | 1999 |
| Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era JN Gerson, E Handorf, D Villa, AS Gerrie, P Chapani, S Li, LJ Medeiros, ... Journal of Clinical Oncology 37 (6), 471-480, 2019 | 87 | 2019 |
| Cancer in people living with HIV, version 1.2018, NCCN clinical practice guidelines in oncology E Reid, G Suneja, RF Ambinder, K Ard, R Baiocchi, SK Barta, ... Journal of the National Comprehensive Cancer Network 16 (8), 986-1017, 2018 | 85 | 2018 |
| NCCN guidelines insights: primary cutaneous lymphomas, version 2.2020: featured updates to the NCCN guidelines N Mehta-Shah, SM Horwitz, S Ansell, WZ Ai, J Barnes, SK Barta, ... Journal of the National Comprehensive Cancer Network 18 (5), 522-536, 2020 | 81 | 2020 |
| Diffuse large B‐cell lymphoma with primary treatment failure: ultra‐high risk features and benchmarking for experimental therapies LJ Costa, K Maddocks, N Epperla, NM Reddy, R Karmali, E Umyarova, ... American journal of hematology 92 (2), 161-170, 2017 | 81 | 2017 |
| NCCN guidelines insights: acute lymphoblastic leukemia, version 1.2017 PA Brown, B Shah, A Fathi, M Wieduwilt, A Advani, P Aoun, SK Barta, ... Journal of the National Comprehensive Cancer Network 15 (9), 1091-1102, 2017 | 75 | 2017 |
| New antibody approaches to lymphoma therapy T Suresh, LX Lee, J Joshi, SK Barta Journal of hematology & oncology 7, 1-12, 2014 | 73 | 2014 |
Joseph SparanoIcahn School of Medicine at Mount SinaiVerified email at mssm.edu
